Regulatory consequences of “Brexit” for the development of medicinal products

Jackson, Emily ORCID: 0000-0002-2052-2776, Feldschreiber, P and Breckenridge, A (2017) Regulatory consequences of “Brexit” for the development of medicinal products. Clinical Pharmacology and Therapeutics, 102. pp. 183-184. ISSN 0009-9236

Preview

Text - Accepted Version Download (348kB) | Preview

• Author

Abstract

The United Kingdom voted in a referendum in June 2016 to leave the European Union (EU) after 45 years of membership. Among the many political, social, and scientific consequences are those for the regulation of health care products. No longer will the efficacy, safety, and quality of medicines in the United Kingdom be subject to an EU regulatory framework. The European Medicines Agency (EMA), which is currently located in London, will move elsewhere in Europe. The pharmaceutical industry will reassess its commitment to the UK health scene.

Item Type:	Article
Official URL:	http://ascpt.onlinelibrary.wiley.com/hub/journal/1...
Additional Information:	© 2017 American Society for Clinical Pharmacology and Therapeutics
Divisions:	Law
Subjects:	J Political Science > JN Political institutions (Europe) J Political Science > JN Political institutions (Europe) > JN101 Great Britain K Law > KD England and Wales R Medicine > RS Pharmacy and materia medica
Date Deposited:	10 Jul 2017 10:58
Last Modified:	12 Dec 2024 01:30
URI:	http://eprints.lse.ac.uk/id/eprint/83347

Actions (login required)

View Item